Home / Market News / $TEM

$TEM news and market catalysts

The 44 most recent market catalysts affecting $TEM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

44 catalysts 8 high impact 29 bullish 6 bearish Healthcare
Nov 18, 2026 Corporate Catalyst Bullish Impact 55
AstraZeneca and Tempus AI Extend Master Services Agreement
Tempus AI and AstraZeneca have formally extended their master services agreement, which means their existing commercial and clinical collaboration will continue. This matters becau…
Nov 9, 2026 Corporate Catalyst Bullish Impact 55
Tempus AI Partners with SOTERIA to Advance Precision Oncology for Military and Veterans
Tempus AI has partnered with the SOTERIA Precision Medicine Foundation to launch the 'Cancer Hunt™' initiative. This collaboration aims to provide precision oncology patient naviga…
Nov 4, 2026 Corporate Catalyst Neutral Impact 65
Wall Street Analysts Update Ratings and Price Targets for Tempus AI
On November 4, 2026, Tempus AI received updated coverage from several Wall Street analysts. Mizuho Securities initiated coverage with a 'buy' rating and a $120 price target, while …
Nov 3, 2026 Corporate Catalyst Bullish Impact 65
Jefferies Upgrades Tempus AI to Hold
Jefferies upgraded Tempus AI's rating from Underperform to Hold and doubled its price target from $35 to $70. This significant revision suggests a more optimistic view from the ana…
Nov 2, 2026 Corporate Catalyst Neutral Impact 75
Tempus AI Receives Regulatory Clearance for Personalis Acquisition
Tempus AI has successfully navigated the regulatory review process for its planned acquisition of Personalis. This is a crucial step forward for the deal, removing a significant po…
Oct 26, 2026 Corporate Catalyst Bullish Impact 55
H.C. Wainwright Maintains Buy Rating and Raises Price Target for Tempus AI
H.C. Wainwright analyst Yi Chen maintained a 'Buy' rating on Tempus AI and raised the price target to $68. This analyst action signals increased confidence in the company's valuati…
Oct 26, 2026 Corporate Catalyst Bullish Impact 55
Tempus AI Receives IVDR Certification for xR RNA Sequencing Assay
Tempus AI's xR assay has achieved Class C IVDR certification in the European Union. This is a significant regulatory milestone as it validates the company's quality management syst…
Oct 23, 2026 Corporate Catalyst Bullish Impact 85
Tempus AI Expands Strategic Partnership with Bristol Myers Squibb and Pathos AI
Tempus AI announced a significant expansion of its strategic partnership with Bristol Myers Squibb and a new collaboration with Pathos AI, securing $192.5 million in cash commitmen…
Oct 19, 2026 Corporate Catalyst Bullish Impact 65
Tempus AI To Present Results From Study Evaluating AI-Enabled Pre-Screening Panel For Patients With Advanced Non-Small Cell Lung Cancer, At ESMO Congress 2026
Tempus AI disclosed positive results from a study evaluating its AI-enabled pre-screening panel for advanced NSCLC, presented at ESMO 2026. The panel showed greater than 80% sensit…
Oct 12, 2026 Corporate Catalyst Bullish Impact 65
Canaccord Genuity Maintains Buy on Tempus AI, Raises Price Target to $95
Canaccord Genuity analyst Kyle Mikson has raised the price target for Tempus AI (TEM) from $80 to $95 while maintaining a 'Buy' rating. This upgrade indicates a more optimistic out…
Oct 7, 2026 Corporate Catalyst Bullish Impact 65
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Tempus AI (TEM) announced an expansion of its existing multi-year collaboration with Moderna (MRNA) and Merck (MRK) for their individualized neoantigen therapy (INT) for melanoma a…
Oct 1, 2026 Corporate Catalyst Bullish Impact 65
Guggenheim Maintains Buy on Tempus AI, Raises Price Target to $92
Guggenheim analyst Subbu Nambi maintained a 'Buy' rating on Tempus AI (TEM) and raised the price target from $65 to $92. This substantial increase in the price target, representing…
Sep 28, 2026 Corporate Catalyst Bullish Impact 65
Tempus AI Receives 510(k) Clearance From FDA For Tempus ECG-MR, AI Product That Analyzes Standard 12-Lead Resting Ecgs To Detect Signs Associated With Undiagnosed Mitral Regurgitation
Tempus AI has secured FDA 510(k) clearance for its ECG-MR product, an AI-powered tool for early detection of mitral regurgitation. This is significant as it adds a new, approved di…
Sep 21, 2026 Corporate Catalyst Bullish Impact 65
Tempus AI Extends Recursion Data Deal Through 2029, Replacing Potential $84M Fees With $42M In Committed Payments, In Addition To Licensing Recursion’s RNA Foundation Model "TxFM" Under A Separate License Agreement
Tempus AI (TEM) and Recursion Pharmaceuticals (RXRX) have extended their data partnership through November 2029. This is significant because Tempus secures continued access to Recu…
Sep 21, 2026 Corporate Catalyst Neutral Impact 65
Goldman Sachs Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $75
Goldman Sachs, a prominent investment bank, has initiated coverage on Tempus AI (TEM) with a 'Neutral' rating and a $75 price target. This event is significant because it marks the…
Sep 18, 2026 Market Technicals Bearish Impact 55
Why Is Tempus AI Stock Falling Friday?
Tempus AI (TEM) stock experienced a decline on Friday, primarily due to a broader market weakening and profit-taking after a strong multi-day rally. The rally was driven by CEO Eri…
Sep 11, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Tempus AI, Raises Price Target to $66
HC Wainwright & Co. analyst Yi Chen maintained a 'Buy' rating on Tempus AI (TEM) and raised the price target from $56 to $66. This analyst action signals continued confidence in th…
Sep 9, 2026 Corporate Catalyst Bullish Impact 75
Tempus AI Selected By Advanced Research Projects Agency For Health To Be Awarded $9.5M For First Autonomous Clinical AI Agent
Tempus AI (TEM) announced it has been selected by ARPA-H to receive up to $9.5 million to develop an autonomous clinical AI agent for heart failure. This is a significant positive …
Sep 9, 2026 Corporate Catalyst Neutral Impact 55
UBS Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $70
UBS analyst Doug Schenkel has initiated coverage on Tempus AI (TEM) with a Neutral rating and a $70 price target. This event is significant for Tempus AI as it marks the formal ent…
Sep 8, 2026 Corporate Catalyst Neutral Impact 55
Rothschild & Co Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $67
Rothschild & Co analyst Jamie Clark has initiated coverage on Tempus AI (TEM) with a 'Neutral' rating and a price target of $67. This event is significant for Tempus AI as it marks…
Sep 8, 2026 Corporate Catalyst Neutral Impact 55
Roth Capital Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $67
Roth Capital's initiation of coverage on Tempus AI (TEM) with a 'Neutral' rating and a $67 price target is a notable event for the company. For newly public companies, analyst cove…
Sep 2, 2026 Corporate Catalyst Bullish Impact 75
Tempus AI's Data Business Is Priced Like a Vendor, Not a Platform, Analyst Says
Cantor Fitzgerald initiated coverage on Tempus AI (TEM) with an 'Overweight' rating and an $80 price target, significantly above its current trading price. The core of the analyst'…
Sep 2, 2026 Corporate Catalyst Bullish Impact 75
TEM stock has given up its prior gain. Tempus AI shares were trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced an $80 price target.
The initiation of coverage by a reputable firm like Cantor Fitzgerald with an 'Overweight' rating and a substantial price target is typically a significant positive catalyst for a …
Sep 2, 2026 Corporate Catalyst Bullish Impact 75
Tempus AI shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced an $80 price target.
This headline represents a significant corporate catalyst for Tempus AI. Analyst initiation with a positive rating ('Overweight') and a substantial price target ($80) often acts as…
Sep 2, 2026 Corporate Catalyst Neutral Impact 65
Cantor Fitzgerald Initiates Coverage On Tempus AI with Overweight Rating, Announces Price Target of $80
Cantor Fitzgerald's initiation of coverage on Tempus AI (TEM) with an 'Overweight' rating and an $80 price target is a significant event for the newly public company. This provides…
Sep 2, 2026 Corporate Catalyst Neutral Impact 65
Cathie Wood Sells $15.6 Million of Tempus AI Stock After Merck-Moderna Trial Win, Ark Keeps Selling AMD Shares
Cathie Wood's Ark Invest made notable portfolio adjustments. The sale of $15.6 million in Tempus AI (TEM) shares comes after a significant price surge, likely representing profit-t…
Sep 1, 2026 Corporate Catalyst Bullish Impact 65
Piper Sandler Upgrades Tempus AI to Overweight, Raises Price Target to $76
Piper Sandler analyst David Westenberg upgraded Tempus AI (TEM) from Neutral to Overweight and raised the price target from $56 to $76. This analyst action signals a more optimisti…
Aug 24, 2026 Corporate Catalyst Bearish Impact 65
What’s Going On With Tempus AI Stock on Monday?
Tempus AI's stock is experiencing a short-term pullback after a substantial 20% surge, which was primarily fueled by positive clinical trial results from Merck and Moderna for an a…
Aug 24, 2026 Corporate Catalyst Bullish Impact 65
Tempus AI Receives FDA Clearance For Tempus ECG-PH For Signs Associated With Pulmonary Hypertension
Tempus AI (TEM) has received FDA 510(k) clearance for its Tempus ECG-PH, an AI-powered device that analyzes standard ECGs for signs of pulmonary hypertension. This is a significant…
Aug 21, 2026 Corporate Catalyst Bullish Impact 85
Tempus AI Stock Climbs Friday: What's Driving the Move?
Tempus AI's stock is experiencing a significant surge following the announcement of positive Phase 3 clinical trial results for a personalized cancer treatment developed by Merck a…
Aug 20, 2026 Corporate Catalyst Bullish Impact 75
Tempus AI shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $70 to $80.
This headline indicates a significant positive catalyst for Tempus AI (TEM). An analyst firm maintaining a 'Buy' rating and, more importantly, raising its price target, suggests a …
Aug 20, 2026 Corporate Catalyst Bullish Impact 85
Why Is Tempus AI Stock Gaining Thursday?
Tempus AI (TEM) stock is experiencing a significant uplift due to a combination of factors. BTIG maintained a Buy rating and raised its price target to $80, signaling strong analys…
Aug 20, 2026 Corporate Catalyst Bullish Impact 55
BTIG Maintains Buy on Tempus AI, Raises Price Target to $80
BTIG analyst Mark Massaro has maintained a 'Buy' rating on Tempus AI (TEM) and raised the price target from $70 to $80. This action signals increased confidence from the analyst in…
Aug 19, 2026 Corporate Catalyst Bullish Impact 95
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition
Merck and Moderna announced successful Phase 3 trial results for their personalized mRNA cancer therapy, INTerpath-001, which significantly improved recurrence-free survival in mel…
Aug 7, 2026 Corporate Catalyst Bullish Impact 65
Why Is Tempus AI Stock Surging on Friday?
Tempus AI (TEM) is experiencing a significant stock surge, primarily driven by a positive sentiment shift across the AI-healthcare technology sector. This rally was ignited by Doxi…
Aug 4, 2026 Corporate Catalyst Bullish Impact 65
Tempus AI Announces Publication Of Study Results In 'Nature Medicine' That Demonstrate The PRISM2 Pathology Foundation Model's Ability To Perform Clinically Important Diagnostic Tasks
Tempus AI's announcement of the 'Nature Medicine' publication validates the efficacy and advanced capabilities of its PRISM2 AI model. This is significant because 'Nature Medicine'…
Jul 31, 2026 Corporate Catalyst Bearish Impact 85
Tempus AI Stock Slides Friday: What's Driving the Post-Earnings Reset?
Tempus AI reported Q2 earnings that technically beat analyst expectations for both revenue and EPS. However, the market is reacting negatively due to a perceived cooling of revenue…
Jul 30, 2026 Corporate Catalyst Bearish Impact 75
Why Nancy Pelosi-Owned Tempus AI Stock Is Down After Q2 Earnings
Tempus AI (TEM) reported Q2 revenue of $382.5 million, beating estimates, and a loss of 4 cents per share, also better than expected. The company raised its full-year revenue guida…
Jul 30, 2026 Corporate Catalyst Bullish Impact 75
Tempus AI Raises FY2026 Sales Guidance from $1.590B-$1.600B to $1.595B-$1.605B vs $1.593B Est
Tempus AI (TEM) has updated its financial outlook for FY2026, increasing its sales guidance range from $1.590 billion-$1.600 billion to $1.595 billion-$1.605 billion. This upward r…
Jul 30, 2026 Corporate Catalyst Bullish Impact 92
Tempus AI Q2 Adj. EPS $(0.04) Beats $(0.14) Estimate, Sales $382.486M Beat $379.743M Estimate
Tempus AI (TEM) announced Q2 adjusted EPS of $(0.04), significantly beating the analyst consensus of $(0.14), and sales of $382.486 million, which also surpassed the $379.743 milli…
Jul 21, 2026 Corporate Catalyst Neutral Impact 92
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
Tempus AI's acquisition of Personalis for $1.5 billion is a significant strategic move aimed at dominating the $20 billion minimal residual disease (MRD) market. This merger is exp…
Jul 20, 2026 Corporate Catalyst Bearish Impact 75
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks
Tempus AI's announcement of a $1.5 billion all-stock acquisition of Personalis has triggered a significant selloff in TEM shares, primarily due to fears of shareholder dilution. Th…
Jul 20, 2026 Corporate Catalyst Bearish Impact 92
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition
Tempus AI's acquisition of Personalis for $1.5 billion is a significant strategic move to enhance its position in the rapidly growing minimal residual disease (MRD) market for canc…
Jul 16, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Maintains Buy on Tempus AI, Raises Price Target to $65
Guggenheim analyst Subbu Nambi maintained a 'Buy' rating on Tempus AI (TEM) and raised the price target from $60 to $65. This action signals continued confidence in the company's p…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.